Brokerages Set NervGen Pharma (NASDAQ:NGEN) Price Target at $18.00

NervGen Pharma (NASDAQ:NGEN) has earned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, one has issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $18.00.

Several research analysts recently commented on NGEN shares. Wall Street Zen downgraded NervGen Pharma from a “hold” rating to a “sell” rating in a research note on Sunday. Weiss Ratings started coverage on shares of NervGen Pharma in a report on Friday, April 24th. They set a “sell (d-)” rating for the company. TD Cowen started coverage on shares of NervGen Pharma in a research report on Thursday, June 11th. They issued a “buy” rating for the company. Stifel Nicolaus raised shares of NervGen Pharma to a “strong-buy” rating in a research note on Thursday, April 23rd. Finally, HC Wainwright upgraded shares of NervGen Pharma to a “strong-buy” rating in a research report on Tuesday, April 28th.

NervGen Pharma Stock Performance

NASDAQ:NGEN opened at $1.88 on Monday. NervGen Pharma has a 12 month low of $1.70 and a 12 month high of $6.30. The business’s 50 day moving average price is $2.48. The stock has a market cap of $151.59 million and a price-to-earnings ratio of -20.89.

NervGen Pharma (NASDAQ:NGEN) last announced its earnings results on Friday, May 15th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02).

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.